Document:

Exhibit 10.1 

      

      

      
        THIRD LEASE AMENDMENT

        

        

        This Lease Amendment made this 9th day of September, 2021 by and between DUKE & DUKE, a Limited Partnership,
          of 37000 Grand River Avenue, Suite 360, Farmington Hills, MI 48335, as “LANDLORD” and Ocuphire Pharma, Inc. of 37000 Grand River Avenue, Suite 120, Farmington Hills, MI 48335, as “TENANT’.

        

        

        WITNESSETH

        

        

        WHEREAS, on or about the 31st day of August, 2021, Landlord and Tenant
          entered into a Lease Agreement with a First Amendment on October 29, 2019, and a Second Amendment on November 17, 2020. The Lease together with any and all Amendments and/or riders is herein collectively referred to as, “Lease”. The certain
          demised premises consists of 1,623 rentable square feet and being commonly known as Suite 120 at 37000 Grand River Avenue, Farmington Hills, MI 48335; and

         

        WHEREAS, the parties wish to amend this Lease in respect to the demised premises in that Tenant will extend the term of the Lease; and

        

        

        NOW THEREFORE, in consideration of monies to be paid and covenants and conditions to be performed, IT IS HEREBY AGREED AS FOLLOWS:

        

        

        	

              	1.	
                That the rent for the Suite known as Suite 120 will be as follows;

              

         

        

        
          
            
              
                	 	
                        01/01/2022 – 12/31/2022

                      	
                        $22.00 per rentable square foot

                      

              

            

          

        

        

        

        	

              	2.	
                That the expiration date of Tenant’s Lease shall be December 31, 2022.

              

        

        

        
          
            
              	

                    	3.

                    	Tenant Share: 	2.13%

            

          

        

         

        

        
          
            	

                  	4.

                  	Base Tax:

                  	$1.39

          

        

        

        

        5.            Miscellaneous: The Lease remains in full force and effect and has not been
            modified or extended except as specifically set in this Third Amendment and extension of lease agreement. To the extent of any conflict between this Amendment and extension of lease agreement and the lease, the provisions of this Third
            Amendment shall control.

        

        

        	
                TENANT:

              	 	
                LANDLORD:

              	 
	 	 	 	 
	
                Ocuphire Pharma, Inc.

              	 	
                DUKE & DUKE,

              	 
	 	 	
                a Limited Partnership

              	 
	 	 	 	 
	
                /s/ Mina Sooch

              	 	
                /s/ Thomas Duke

              	 
	
                Name: Mina Sooch

              	 	
                Name: Thomas Duke

              	 
	
                Its: CEO

              	 	
                Its: Gen Ptnr

              	 
	
                Date: 9/9/2021

              	 	
                Date: 9/9/2021Document

Exhibit 10.2

[LiveVox Holdings Inc. Letterhead]
[●], 2021
[Participant Name]
Re:     Double-Trigger Vesting of RSU Award
Dear [Participant Name]:
Reference is made to that certain Restricted Stock Unit Award Agreement, dated as of [●], 2021 (the “Award Agreement”), by and between LiveVox Holdings, Inc., a Delaware corporation (the “Company”), and you, pursuant to which you were granted an award of restricted stock units (the “RSU Award”) in respect of the common stock, par value $0.0001, of the Company, on the terms and subject to the conditions set forth in the Award Agreement and the Company’s 2021 Equity Incentive Plan (the “Plan”). Capitalized terms used herein without definition have the meanings ascribed to such terms in the Plan.
This letter agreement (this “Agreement”) memorializes our discussion regarding certain accelerated vesting provisions that will apply to the RSU Award if the RSU Award is assumed, continued, or substituted in connection with a Change in Control.
1.Acceleration of Vesting upon a Qualifying Termination of Employment. Notwithstanding Section 2(b) of the Award Agreement, if (a) in connection with a Change in Control, the RSU Award is assumed, continued, or substituted in accordance with Section 13(c)(i) of the Plan (such award as assumed, continued, or substituted, the “Converted RSU Award”) and (b) your Continuous Service is terminated by the Company without Cause or by you with Good Reason (as defined below), in each case, within six months following the consummation of such Change in Control, then, subject to your execution and non-revocation of a general release of claims in favor of the Company and its affiliates in a form provided by the Company, any unvested portion of the Converted RSU Award shall fully vest. Except as set forth in this Section 1, the terms and conditions of the Award Agreement and the Plan shall continue to govern the RSU Award.
2.Definition of Good Reason. For purposes of this Agreement, “Good Reason” means, following a Change in Control, a material diminution in your duties, authorities, or responsibilities during your employment with the Company without your written consent; provided, however, that you shall not have Good Reason (a) solely due to the Company ceasing to be a publicly traded company following the consummation of such Change in Control or due to any attendant changes to your duties, authorities, or responsibilities resulting from the Company ceasing to be a publicly traded company; or (b) if you are offered a senior-level executive position with the Company (or any surviving or acquiring entity in such Change in Control) or any affiliate thereof following such Change in Control and you elect to not accept such position. To invoke a termination of Continuous Service for Good Reason, you must provide written notice to the Company of the existence of one or more of the conditions described in this Section 2 within 30 days following your knowledge of the initial existence of 

such condition or conditions, specifying in reasonable detail the conditions constituting Good Reason, and the Company shall have 30 days following receipt of such written notice during which it may remedy the condition if such condition is reasonably subject to cure. If the Company fails to remedy the condition constituting Good Reason during the applicable cure period, your termination of Continuous Service must occur, if at all, within 30 days following such cure period for such termination as a result of such condition to constitute a termination for Good Reason. Otherwise, any claim of such conditions as Good Reason will be deemed irrevocably waived by you.
3.No Right to Continued Employment. Nothing in this Agreement will confer upon you any right to continued employment with the Company (or its affiliates or their respective successors) or interfere in any way with the right of the Company (or its affiliates or their respective successors) to terminate your employment at any time.
4.Governing Law. This Agreement will be governed by, and construed under and in accordance with, the internal laws of the State of Delaware, without reference to rules relating to conflicts of laws.
5.Entire Agreement; Amendment. This Agreement constitutes the entire agreement between you and the Company with respect to the subject matter hereof and supersedes any and all prior agreements or understandings between you and the Company with respect to the subject matter hereof, whether written or oral. In the event of a conflict between the terms of this Agreement and the Award Agreement, the terms of this Agreement shall control. This Agreement may be amended or modified only by a written instrument executed by you and the Company.
6.Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original but all of which taken together will constitute one and the same instrument.
[Signature Page Follows]
2

This Agreement is intended to be a binding obligation on you and the Company. If this Agreement accurately reflects your understanding as to the terms and conditions of the accelerated vesting provisions relating to the RSU Award, please sign, date, and return to me one copy of this Agreement. You should make a copy of the executed Agreement for your records.
Very truly yours,
LIVEVOX HOLDINGS, INC.

By: ________________________________
       Name:
       Title:
The above terms and conditions accurately reflect our understanding regarding the terms and conditions of the acceleration provisions relating to the RSU Award, and I hereby confirm my agreement to the same.

____________________________________
[Participant Name]
[Signature Page to Double-Trigger Vesting Agreement]Exhibit
10.1

 

NON-EMPLOYEE
DIRECTOR COMPENSATION PROGRAM

 

The
Stereotaxis, Inc. Non-Employee Director Compensation program effective July 1, 2021:

 

Annual
Awards of Restricted Share Units (“RSUs”)

 

	Annual
    award to each director	RSUs
    equal to $200,000 

 

All
equity awards to directors will be issued under the Stereotaxis, Inc. 2012 Stock Incentive Plan or a successor Plan.

 

Annual
equity awards will be made in two installments on the first business day of January and the first business day of July in each calendar
year, paid in arrears and pro-rated according to the length of time served as a director. The value of each semi-annual installment will
equal $100,000. The number of RSUs issued at each semi-annual installment will be calculated by dividing a) the total semi-annual grant
value of $100,000 by b) the adjusted closing per share on the accounting grant date for each semi-annual period.

 

The
RSUs will vest on the earliest to occur of (i) the fifth anniversary of the date of the award, (ii) the date on which the service of
the director on the board of directors terminates, or (iii) a Change of Control of the Company. Notwithstanding the foregoing, directors
receiving an award of RSUs may elect to receive the RSUs pursuant to an alternate vesting schedule under which the RSUs will vest immediately
but will be subject to a one year limit on trading, provided that such an election is made in the year preceding the year in which the
RSUs are earned.

 

Notwithstanding
anything in this Program to the contrary, this program and each award is intended to comply with the requirements imposed by Internal
Revenue Code Section 409A. If any program provision or award would result in the imposition of an additional tax under Section 409A of
the Code, the Company and the director intend that the program provision or award will be reformed to avoid imposition, to the extent
possible, of the applicable tax and no action taken to comply with Section 409A of the Code shall be deemed to adversely affect the director’s
rights to an award. The director further agrees that the Company, in the exercise of its sole discretion and without the consent of the
Director, may amend or modify an award in any manner and delay the payment of any amounts payable pursuant to an award to the minimum
extent necessary to meet the requirements of Section 409A of the Code as the Company deems appropriate or desirable. Notwithstanding
anything in the program, an award, or any other agreement (written or oral) to the contrary, if the director is a “specified employee”
(within the meaning of Code Section 409A) on the date of separation from service, any payments made with respect to such separation from
service under any award will be delayed to the extent necessary to comply with Section 409A(a)(2)(B)(i) of the Code, and such payments
or benefits will be paid or distributed to the director during the five-day period commencing on the expiration of the six-month period
measured from the date of the director’s separation from service. Upon the expiration of the applicable six-month period under
Section 409A(a)(2)(B)(i) of the Code, all payments so deferred will be paid to the director in a lump sum payment without interest. Any
remaining payments and benefits due under an award will be paid as otherwise provided in the award.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]